Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc., held on June 16, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in New York, NY. Approximately 89.98% of eligible outstanding shares were present in person or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The stockholders voted on three proposals with the following outcomes:
- Proposal One (Election of Directors): Approved. Eight directors were elected. While all nominees received majority support, significant votes were withheld for Pedro Granadillo (4,625,999), Gotham Makker (4,643,002), and Naveen Yalamanchi (6,746,815).
- Proposal Two (Ratification of Accounting Firm): Approved. Stockholders ratified the appointment of EisnerAmper LLP for the fiscal year ending December 31, 2020.
- Proposal Three (Stockholder Proposal): Not Approved. A proposal to implement majority voting in uncontested director elections was defeated, with 22,047,356 votes against versus 20,193,145 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the specific reasons for the high number of votes withheld for directors Pedro Granadillo, Gotham Makker, and Naveen Yalamanchi.
- Confirm the rationale behind the rejection of the majority voting proposal for uncontested director elections.
- Review the company's most recent 10-K or 10-Q for financial performance data not included in this 8-K.